Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Show more...
CEO
Çalışanlar
50
Ülke
Amerika Birleşik Devletleri
ISIN
US54300N1037
Kotasyonlar
0 Comments
Düşüncelerini paylaş
FAQ
Longboard Pharmaceuticals hissesinin bugünkü fiyatı nedir?▼
LBPH’un güncel fiyatı $60.04 USD — son 24 saatte %+0.13% arttı. Longboard Pharmaceuticals hissesinin fiyat performansını grafikte daha yakından izle.